The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index.
MicroRNA and cancer
Open accessAbstract
With the advent of next generation sequencing techniques a previously unknown world of non‐coding RNA molecules have been discovered. Non‐coding RNA transcripts likely outnumber the group of protein coding sequences and hold promise of many new discoveries and mechanistic explanations for essential biological phenomena and pathologies. The best characterized non‐coding RNA family consists in humans of about 1400 microRNAs for which abundant evidence have demonstrated fundamental importance in normal development, differentiation, growth control and in human diseases such as cancer. In this review, we summarize the current knowledge and concepts concerning the involvement of microRNAs in cancer, which have emerged from the study of cell culture and animal model systems, including the regulation of key cancer‐related pathways, such as cell cycle control and the DNA damage response. Importantly, microRNA molecules are already entering the clinic as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
RetractedA TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function
Melo, S. A., Ropero, S., Moutinho, C., Aaltonen, L. A., Yamamoto, H., Calin, G. A., Rossi, S., Fernandez, A. F., Carneiro, F., Oliveira, C., et al. (2009) · Nature Genetics · doi:10.1038/ng.317 · Cited by 373
RetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Salmena, L., Poliseno, L., Tay, Y., Kats, L., & Pandolfi, P. P. (2011) · Cell · doi:10.1016/j.cell.2011.07.014 · Cited by 7,262
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Cited by
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., Brenner, A. J., Park, K., Lee, J.-L., Kim, T.-Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0802-1 · Cited by 975
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
MicroRNA and cancer – A brief overview
Acunzo, M., Romano, G., Wernicke, D., & Croce, C. M. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.013 · Cited by 630
Reddy, K. B. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0185-1 · Cited by 613
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance
Iqbal, M. A., Arora, S., Prakasam, G., Calin, G. A., & Syed, M. A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.003 · Cited by 449
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Clustered miRNAs and their role in biological functions and diseases
Kabekkodu, S. P., Shukla, V., Varghese, V. K., D' Souza, J., Chakrabarty, S., & Satyamoorthy, K. (2018) · Biological Reviews · doi:10.1111/brv.12428 · Cited by 358
Pakravan, K., Babashah, S., Sadeghizadeh, M., Mowla, S. J., Mossahebi-Mohammadi, M., Ataei, F., Dana, N., & Javan, M. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0335-7 · Cited by 346
Liquid biopsy in breast cancer: A comprehensive review
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019) · Clinical Genetics · doi:10.1111/cge.13514 · Cited by 332
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
The Potential of MicroRNAs as Prostate Cancer Biomarkers
Fabris, L., Ceder, Y., Chinnaiyan, A. M., Jenster, G. W., Sorensen, K. D., Tomlins, S., Visakorpi, T., & Calin, G. A. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.054 · Cited by 311
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Phase Separation as a Missing Mechanism for Interpretation of Disease Mutations
Tsang, B., Pritišanac, I., Scherer, S. W., Moses, A. M., & Forman-Kay, J. D. (2020) · Cell · doi:10.1016/j.cell.2020.11.050 · Cited by 281
Liu, Y., Luo, F., Wang, B., Li, H., Xu, Y., Liu, X., Shi, L., Lu, X., Xu, W., Lu, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.011 · Cited by 275
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions
Matsuhashi, S., Manirujjaman, M., Hamajima, H., & Ozaki, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092304 · Cited by 143
Lo, T.-F., Tsai, W.-C., & Chen, S.-T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075628 · Cited by 122
A mouse tissue atlas of small noncoding RNA
Isakova, A., Fehlmann, T., Keller, A., & Quake, S. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002277117 · Cited by 119
MicroRNA-21's role in PTEN suppression and PI3K/AKT activation: Implications for cancer biology
Chawra, H. S., Agarwal, M., Mishra, A., Chandel, S. S., Singh, R. P., Dubey, G., Kukreti, N., & Singh, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155091 · Cited by 91
Alizadeh Savareh, B., Asadzadeh Aghdaie, H., Behmanesh, A., Bashiri, A., Sadeghi, A., Zali, M., & Shams, R. (2020) · Pancreatology · doi:10.1016/j.pan.2020.07.399 · Cited by 74
Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins
Harden, M. E., Prasad, N., Griffiths, A., & Munger, K. (2017) · mBio · doi:10.1128/mbio.02170-16 · Cited by 64
miRNAs as therapeutic tools and biomarkers for prostate cancer
Arrighetti, N., & Beretta, G. L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030380 · Cited by 43
Choi, K. H., Shin, C. H., Lee, W. J., Ji, H., & Kim, H. H. (2019) · Bioscience Reports · doi:10.1042/bsr20190634 · Cited by 42
Monnaka, V. U., Hernandes, C., Heller, D., & Podgaec, S. (2021) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2021rw5704 · Cited by 33
A comprehensive overview of liquid biopsy applications in pediatric solid tumors
Janssen, F. W., Lak, N. S. M., Janda, C. Y., Kester, L. A., Meister, M. T., Merks, J. H. M., van den Heuvel-Eibrink, M. M., van Noesel, M. M., Zsiros, J., Tytgat, G. A. M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00657-z · Cited by 32
MicroRNAs in B-cells: From normal differentiation to treatment of malignancies
Marques, S. C., Laursen, M. B., Bødker, J. S., Kjeldsen, M. K., Falgreen, S., Schmitz, A., Bøgsted, M., Johnsen, H. E., & Dybkaer, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3057 · Cited by 26
Bjerke, G. A., & Yi, R. (2020) · RNA · doi:10.1261/rna.073635.119 · Cited by 22
Ma, F., Huang, J., Li, W., Li, P., Liu, M., & Xue, H. (2022) · Environmental Toxicology · doi:10.1002/tox.23516 · Cited by 15
Valverde, A., Nares, S., & Naqvi, A. R. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194628 · Cited by 15
Metadata
- Authors
- Jansson, M. D., & Lund, A. H.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2012-10-09
- Volume
- 6
- Issue
- 6
- Pages
- 590-610
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W1969192247
- Cited by
- 1,099
- References
- 235
- FWCI
- 20.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.